Tandem Diabetes Care, San Diego, CA, USA.
dQ&A, San Francisco, CA, USA.
J Diabetes Sci Technol. 2020 Mar;14(2):309-317. doi: 10.1177/1932296819897976. Epub 2020 Feb 6.
With the rapid development of new insulin delivery technology, measuring patient experience has become especially pertinent. The current study reports on item development, psychometric validation, and intended use of the newly developed Diabetes Impact and Device Satisfaction (DIDS) Scale.
The DIDS Scale was informed by a comprehensive literature review, and field tested as part of two focus groups. The finalized measure was used at baseline and 6 months post-assessment with a large US cohort. Exploratory factor analyses (EFAs) were conducted to determine and confirm factor structure and item selection. Internal reliability, test-retest reliability, and convergent/divergent validity of the emerged factors were tested with demographics, diabetes-specific information, and diabetes behavioral and satisfaction measures.
In all, 778 participants with type 1 diabetes (66% female, mean age 47.13 ± 17.76 years, 74% insulin pump users) completed surveys at both baseline and post-assessment. EFA highlighted two factors-Device Satisfaction (seven items, Cronbach's α = 0.85-0.90) and Diabetes Impact (four items, Cronbach's α = 0.71-0.75). DIDS Scale demonstrated good concurrent validity and test-retest reliability.
The DIDS Scale is a novel and a brief assessment tool with robust psychometric properties. It is recommended for use across all insulin delivery devices and is considered appropriate for use in longitudinal studies. Future studies are recommended to evaluate the performance of DIDS Scale in diverse populations with diabetes.
随着新胰岛素输送技术的快速发展,衡量患者体验变得尤为重要。本研究报告了新开发的糖尿病影响和设备满意度(DIDS)量表的项目开发、心理测量验证和预期用途。
DIDS 量表的开发参考了全面的文献综述,并作为两个焦点小组的一部分进行了现场测试。经过最终确定的测量方法在基线和 6 个月后评估时用于一个大型美国队列。探索性因素分析(EFAs)用于确定和确认因素结构和项目选择。通过人口统计学、糖尿病特定信息以及糖尿病行为和满意度措施,测试了新兴因素的内部可靠性、重测信度和聚合/发散效度。
共有 778 名 1 型糖尿病患者(66%为女性,平均年龄为 47.13±17.76 岁,74%为胰岛素泵使用者)在基线和后评估时均完成了调查。EFA 突出了两个因素——设备满意度(七个项目,Cronbach's α=0.85-0.90)和糖尿病影响(四个项目,Cronbach's α=0.71-0.75)。DIDS 量表具有良好的同时效性和重测信度。
DIDS 量表是一种新颖且简洁的评估工具,具有可靠的心理测量特性。它推荐用于所有胰岛素输送设备,并被认为适合在纵向研究中使用。建议未来的研究评估 DIDS 量表在不同糖尿病患者群体中的表现。